1009356--3/11/2009--SALIX_PHARMACEUTICALS_LTD

related topics
{product, liability, claim}
{product, candidate, development}
{stock, price, operating}
{product, market, service}
{property, intellectual, protect}
{provision, law, control}
{cost, contract, operation}
We expect to be unprofitable and experience negative cash flow during 2009, and we may need additional capital. Future sales of Xifaxan and our other marketed products might be less than expected. Regulatory approval of our product candidates is time-consuming, expensive and uncertain, and could result in unexpectedly high expenses and delay our ability to sell our products. Our ability to increase revenue in the future will depend in part on our success in in-licensing or acquiring additional pharmaceutical products. Regulatory approval, even if granted, might entail ongoing requirements or restrictions on marketing that could increase our expenses and limit revenue. Failure to comply with manufacturing regulation could harm us financially and could hurt our reputation. Our intellectual property rights might not afford us with meaningful protection. Intense competition might render our products noncompetitive or obsolete. We could be exposed to significant product liability claims that could prevent or interfere with our product commercialization efforts. If third-party payors do not provide coverage or reimburse patients for our products, our ability to derive revenues will suffer. We are dependent on third parties to manufacture our products. We are dependent on third parties to supply us with products. Our results of operations might fluctuate from period to period, and a failure to meet the expectations of investors or the financial community at large could result in a decline in our stock price. Our stock price is volatile. Antitakeover provisions could discourage a takeover that stockholders consider to be in their best interests or prevent the removal of our current directors and management.

Full 10-K form ▸

related documents
34956--8/14/2007--SYNTHETIC_BLOOD_INTERNATIONAL_INC
34956--7/28/2006--SYNTHETIC_BLOOD_INTERNATIONAL_INC
1009356--3/10/2010--SALIX_PHARMACEUTICALS_LTD
1124140--3/12/2010--EXACT_SCIENCES_CORP
1037649--3/16/2006--INTERLEUKIN_GENETICS_INC
1009356--3/14/2008--SALIX_PHARMACEUTICALS_LTD
896778--3/14/2008--CONCEPTUS_INC
896778--3/16/2006--CONCEPTUS_INC
1203866--3/16/2006--PHARMION_CORP
850693--3/6/2006--ALLERGAN_INC
873364--3/13/2006--CEPHALON_INC
873591--3/13/2006--MEDIMMUNE_INC_/DE
850693--3/1/2007--ALLERGAN_INC
816284--2/18/2010--CELGENE_CORP_/DE/
749647--3/27/2009--Celsion_CORP
1114529--3/31/2006--VIACELL_INC
1116463--3/16/2007--ORASURE_TECHNOLOGIES_INC
793279--9/13/2006--CANDELA_CORP_/DE/
1068874--10/12/2006--IMPLANT_SCIENCES_CORP
918112--11/6/2006--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
793279--9/13/2007--CANDELA_CORP_/DE/
793279--9/11/2008--CANDELA_CORP_/DE/
1030206--2/2/2010--VASCULAR_SOLUTIONS_INC
1030206--2/3/2009--VASCULAR_SOLUTIONS_INC
1030206--2/5/2008--VASCULAR_SOLUTIONS_INC
879682--3/30/2007--PLC_SYSTEMS_INC
930184--3/16/2006--VALEANT_PHARMACEUTICALS_INTERNATIONAL
883975--3/11/2010--STEMCELLS_INC
873364--2/28/2007--CEPHALON_INC
883975--3/15/2007--STEMCELLS_INC